News AZ's Alexion extends gMG options with two Klygefa approvals AstraZeneca's Alexion unit has won approval in the US and EU for Klygefa, billed as a future blockbuster, for generalised myasthenia gravis (gMG).
News AZ makes case for hypophosphatasia drug after phase 3 miss AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?
Digital How pharma and start-ups are working together for AI success At the PharmStars Pharmtech Innovation Summit in Boston, start-up founders and pharma executives shared the stage to share lessons on AI deployment.
News Readout for AZ's hypoparathyroidism drug raises questions AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.
News AZ considers filings for long-acting Strensiq follow-up AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.
News AZ trumpets results for new injectable C5 drug for gMG AstraZeneca's gefurulimab could give gMG patients the first treatment option that they can self-administer at home once a week.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.